213 related articles for article (PubMed ID: 28040362)
21. Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.
Nalbandian A; Khan AA; Srivastava R; Llewellyn KJ; Tan B; Shukr N; Fazli Y; Kimonis VE; BenMohamed L
Inflammation; 2017 Feb; 40(1):21-41. PubMed ID: 27730320
[TBL] [Abstract][Full Text] [Related]
22. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
[TBL] [Abstract][Full Text] [Related]
23. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice.
Gao RF; Li X; Xiang HY; Yang H; Lv CY; Sun XL; Chen HZ; Gao Y; Yang JS; Luo W; Yang YQ; Tang YH
Int Immunopharmacol; 2021 Jan; 90():107133. PubMed ID: 33168408
[TBL] [Abstract][Full Text] [Related]
24. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
25. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
Coll RC; Robertson AA; Chae JJ; Higgins SC; Muñoz-Planillo R; Inserra MC; Vetter I; Dungan LS; Monks BG; Stutz A; Croker DE; Butler MS; Haneklaus M; Sutton CE; Núñez G; Latz E; Kastner DL; Mills KH; Masters SL; Schroder K; Cooper MA; O'Neill LA
Nat Med; 2015 Mar; 21(3):248-55. PubMed ID: 25686105
[TBL] [Abstract][Full Text] [Related]
26. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of NLRP3 inflammasome ameliorates podocyte damage by suppressing lipid accumulation in diabetic nephropathy.
Wu M; Yang Z; Zhang C; Shi Y; Han W; Song S; Mu L; Du C; Shi Y
Metabolism; 2021 May; 118():154748. PubMed ID: 33675822
[TBL] [Abstract][Full Text] [Related]
28. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.
Coll RC; Hill JR; Day CJ; Zamoshnikova A; Boucher D; Massey NL; Chitty JL; Fraser JA; Jennings MP; Robertson AAB; Schroder K
Nat Chem Biol; 2019 Jun; 15(6):556-559. PubMed ID: 31086327
[TBL] [Abstract][Full Text] [Related]
29. The effects of NLRP3 inflammasome inhibition or knockout in experimental apical periodontitis induced in mice.
Pucinelli CM; da Silva RAB; Nelson-Filho P; Lima RB; Lucisano MP; Marchesan JT; da Silva LAB
Clin Oral Investig; 2024 Apr; 28(5):285. PubMed ID: 38684528
[TBL] [Abstract][Full Text] [Related]
30. Second-Generation Antidiabetic Sulfonylureas Inhibit Candida albicans and Candidalysin-Mediated Activation of the NLRP3 Inflammasome.
Lowes DJ; Hevener KE; Peters BM
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712208
[TBL] [Abstract][Full Text] [Related]
31. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.
van Hout GP; Bosch L; Ellenbroek GH; de Haan JJ; van Solinge WW; Cooper MA; Arslan F; de Jager SC; Robertson AA; Pasterkamp G; Hoefer IE
Eur Heart J; 2017 Mar; 38(11):828-836. PubMed ID: 27432019
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the NLRP3 inflammasome reduces brain edema and regulates the distribution of aquaporin-4 after cerebral ischaemia-reperfusion.
Wang H; Chen H; Jin J; Liu Q; Zhong D; Li G
Life Sci; 2020 Jun; 251():117638. PubMed ID: 32251636
[TBL] [Abstract][Full Text] [Related]
33. Evidence against a role for NLRP3-driven islet inflammation in db/db mice.
Kammoun HL; Allen TL; Henstridge DC; Barre S; Coll RC; Lancaster GI; Cron L; Reibe S; Chan JY; Bensellam M; Laybutt DR; Butler MS; Robertson AAB; O'Neill LA; Cooper MA; Febbraio MA
Mol Metab; 2018 Apr; 10():66-73. PubMed ID: 29478918
[TBL] [Abstract][Full Text] [Related]
34. α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β
Ebrahimi T; Rust M; Kaiser SN; Slowik A; Beyer C; Koczulla AR; Schulz JB; Habib P; Bach JP
J Neuroinflammation; 2018 Sep; 15(1):282. PubMed ID: 30261895
[TBL] [Abstract][Full Text] [Related]
35. NLRP3 Inflammasome and Mineralocorticoid Receptors Are Associated with Vascular Dysfunction in Type 2 Diabetes Mellitus.
Ferreira NS; Bruder-Nascimento T; Pereira CA; Zanotto CZ; Prado DS; Silva JF; Rassi DM; Foss-Freitas MC; Alves-Filho JC; Carlos D; Tostes RC
Cells; 2019 Dec; 8(12):. PubMed ID: 31817997
[TBL] [Abstract][Full Text] [Related]
36. MCC950 Inhibits NLRP3 Inflammasome and Alleviates Axonal Injures in Early Stages of Diffuse Axonal Injury in Rats.
Zhao J; Guo X; Wang B; Yang Z; Huang T; Guo D; Zhang M; Song J
Neurochem Res; 2020 Sep; 45(9):2020-2031. PubMed ID: 32474832
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice.
Dempsey C; Rubio Araiz A; Bryson KJ; Finucane O; Larkin C; Mills EL; Robertson AAB; Cooper MA; O'Neill LAJ; Lynch MA
Brain Behav Immun; 2017 Mar; 61():306-316. PubMed ID: 28003153
[TBL] [Abstract][Full Text] [Related]
38. Podocyte Activation of NLRP3 Inflammasomes Contributes to the Development of Proteinuria in Lupus Nephritis.
Fu R; Guo C; Wang S; Huang Y; Jin O; Hu H; Chen J; Xu B; Zhou M; Zhao J; Sung SJ; Wang H; Gaskin F; Yang N; Fu SM
Arthritis Rheumatol; 2017 Aug; 69(8):1636-1646. PubMed ID: 28544564
[TBL] [Abstract][Full Text] [Related]
39. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice.
Ludwig-Portugall I; Bartok E; Dhana E; Evers BD; Primiano MJ; Hall JP; Franklin BS; Knolle PA; Hornung V; Hartmann G; Boor P; Latz E; Kurts C
Kidney Int; 2016 Sep; 90(3):525-39. PubMed ID: 27262364
[TBL] [Abstract][Full Text] [Related]
40. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
McElvaney OJ; Zaslona Z; Becker-Flegler K; Palsson-McDermott EM; Boland F; Gunaratnam C; Gulbins E; O'Neill LA; Reeves EP; McElvaney NG
Am J Respir Crit Care Med; 2019 Dec; 200(11):1381-1391. PubMed ID: 31454256
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
